acromegaly/diarré

Länken sparas på Urklipp

Välj sorteringstyp

Sida 1 från 41 resultat

An open, phase III study of lanreotide (Somatuline PR) in the treatment of acromegaly.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Acromegaly is a disorder caused by excessive secretion of human growth hormone (GH). Somatostatin and its analogue-prolonged release formulation, lanreotide (Somatuline PR), inhibit the secretion of growth hormone. The aim of this open Phase III study was to investigate the clinical efficacy of

Role of a long-acting somatostatin analogue (SMS 201-995) in the treatment of acromegaly.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

The beneficial effect of the long-acting analogue of somatostatin SMS 201-995 in the treatment of acromegaly is described in three cases, and current published experience is reviewed. A total of 64 patients from 10 series have received the drug from one to 25 months, usually in doses of 50-150

Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Pasireotide (SOM-230) is a small somatostatin (SST) analog that is being developed by Novartis Pharma AG for the potential treatment of acromegaly, Cushing's disease and neuroendocrine tumors; the compound is currently in phase III clinical trials for Cushing's disease. Pasireotide exhibits high

Clinical experience of octreotide in the treatment of acromegaly.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

To evaluate the efficacy and safety of octreotide (a somatostatin analogue) in the treatment of acromegaly, 10 patients were injected subcutaneously with octreotide, 50 micrograms, thrice daily before each meal for two days, followed by 100 micrograms thrice daily for six months. One case dropped

Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE To determine the effects of the new somatostatin analogue, lanreotide, in its prolonged released form (PR), in patients with acromegaly. METHODS Prospective open multicenter non comparative study. METHODS Thirty-three university-affiliated medical centers. METHODS One hundred sixteen

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE To evaluate efficacy and safety of lanreotide autogel (ATG) 120 mg injections every 4-8 weeks in somatostatin analogue-naïve patients with acromegaly. METHODS Open, non-comparative, phase III, multicenter clinical study. METHODS Fifty-one patients (28 women, aged 19-78 yr): 39 newly

Adverse events associated with somatostatin analogs in acromegaly.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND In patients with acromegaly, somatostatin analogs (SSA) represent the first choice medical treatment. The long-acting SSA have been found to be effective in controlling growth hormone and IGF-I levels in a high percentage of patients, resulting in an improvement in the quality of life;

Therapeutic efficacy of a somatostatin analogue (SMS 201-995) in active acromegaly.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Twelve patients with active acromegaly, six of whom had not responded to previous combined surgery, radiotherapy, and bromocriptine administration, were treated with an octapeptide long-acting somatostatin analogue, SMS 201-995, given subcutaneously for up to 1 year. Growth hormone (GH) levels

Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Acromegaly is associated with significant morbidities and a 2- to 3-fold increase in mortality because of the excessive metabolic action of GH and IGF-I, a marker of GH output. Reductions in morbidity correspond with decreases in IGF-I, and mortality is lowered following normalization of IGF-I or GH

Improvement of acromegaly after octreotide LAR treatment.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Octreotide is a somatostatin analog that inhibits growth hormone release showing higher potency than natural somatostatin so it has proved to be effective in acromegaly treatment. The objective of present study was to establish the effects of octreotide LAR (long acting release) preparation in

Resolution of acromegaly, amenorrhea-galactorrhea syndrome, and hypergastrinemia after resection of jejunal carcinoid.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

A young woman presented with acromegaly and amenorrhea-galactorrhea with hypersomatotropinemia and hyperprolactinemia. In addition, she had hypergastrinemia with abnormal secretory dynamics and evidence of a large pituitary tumor with suprasellar extension and erosion of the floor of the sella

Detection of polyps in the small bowel of patients with acromegaly via capsule endoscopy.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

the prevalence of small bowel (SB) polyps is unknown in acromegaly patients.to evaluate the prevalence of polyps/tumors in SB of acromegaly patients.this was a prospective and observational study that compared the prevalence of

Octreotide treatment of acromegaly. A randomized, multicenter study.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE To determine the effects of the somatostatin analog, octreotide acetate, in patients with acromegaly. METHODS Double-blind, randomized trial. METHODS Fourteen university-affiliated medical centers. METHODS One hundred fifteen acromegalic patients, 70% of whom had persistent disease after

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

The objective of the study was to determine the tolerability and effectiveness of the slow release (SR) somatostatin analog lanreotide in active acromegaly. Fifty-seven patients, unselected in terms of their previous responsiveness to octreotide therapy, were included in a prospective, open label

Direct costs of carcinoid syndrome diarrhea among adults in the United States.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

The burden of carcinoid syndrome (CS) among patients with neuroendocrine tumors is substantial and has been shown to result in increased healthcare resource use and costs. The incremental burden of CS diarrhea (CSD) is less well understood, particularly among working age adults who

Tidigare
1
2
3
Nästa

Gå med på vår
facebook-sida

Herbal & Natural Medicine

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

Fungerar på 55 språk
Växtbaserade botemedel som stöds av vetenskap
Örter igenkänning av bild
Interaktiv GPS-karta - märka örter på plats (kommer snart)
Läs vetenskapliga publikationer relaterade till din sökning
Sök efter medicinska örter efter deras effekter
Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning